FDA Approves NUMELVI, First Second-Generation JAK Inhibitor for Canine Allergic Dermatitis
核心洞察
The FDA has approved NUMELVI (搜索) (atinvicitinib (搜索) tablets), the first second-generation JAK inhibitor for controlling pruritus (搜索) in dogs with allergic dermatitis (搜索) aged six months and older.
NUMELVI (搜索) demonstrates at least 10-fold selectivity for JAK1 (搜索) over other JAK proteins, potentially minimizing interference with beneficial immune functions while providing rapid itch relief from the first dose.
The drug addresses a significant veterinary need, as skin conditions account for up to 20% of cases in general veterinary practice and can severely impact quality of life for both dogs and owners.
The U.S. Food and Drug Administration has approved NUMELVI (搜索) (atinvicitinib (搜索) tablets), marking a significant advancement in veterinary dermatology as the first and only second-generation Janus kinase (JAK) inhibitor indicated for controlling pruritus (搜索) associated with allergic dermatitis (搜索) in dogs six months of age and older. Merck Animal Health (搜索) announced the approval on February 25, 2026, with nationwide availability expected in spring 2026.
Addressing a Critical Veterinary Need
Skin conditions represent a substantial burden in veterinary medicine, accounting for up to 20% of cases seen in general veterinary practice. As allergic dermatitis (搜索) progresses, the condition significantly impacts quality of life for both dogs and their owners due to physical discomfort, emotional distress, and disruptions in sleep and daily routines caused by persistent itchiness and skin lesions.
"Merck Animal Health (搜索) is proud to introduce NUMELVI (搜索), our latest advancement geared at rapidly controlling pruritus (搜索) associated with allergic dermatitis (搜索), a common condition that causes distress for so many pets and pet owners," said Christine McKinney, DVM, DACVD and Senior Professional Services Veterinarian at Merck Animal Health.
Advanced JAK1 Selectivity Profile
NUMELVI (搜索) distinguishes itself through its high selectivity for JAK1 (搜索), demonstrating at least 10-fold greater selectivity for JAK1 compared to JAK2 (搜索), JAK3 (搜索), and TYK2 (搜索) in in vitro assays. This selectivity profile allows the drug to inhibit JAK1-dependent cytokines involved in itch and inflammation associated with allergic dermatitis (搜索), including atopic dermatitis (搜索), while potentially minimizing interference with the beneficial immune functions of other JAK proteins.
The enhanced selectivity contributes to what Merck describes as a compelling safety profile with proven efficacy, offering significant reduction in itch from the first dose. Tim Kowalski, Distinguished Scientist in Discovery Research at Merck Animal Health (搜索), emphasized the significance of bringing second-generation JAK inhibitor technology to veterinary medicine, noting that such inhibitors are already considered standard of care in human health.
Clinical and Practical Advantages
NUMELVI (搜索) is approved for dogs weighing at least 4.4 pounds (2 kg), with most dogs requiring only one tablet or half a tablet once daily. The treatment offers several practical benefits for veterinary clinics, including no need to adjust vaccination schedules and standard storage conditions.
The drug's active ingredient demonstrates intrinsic stability, eliminating the need for protective film coating or specialized packaging. This stability contributes to what Merck claims is the longest shelf life among JAK inhibitor tablets in veterinary medicine, enhancing convenience for both veterinarians and pet owners.
Market Position and Availability
As the only JAK inhibitor approved in the United States for controlling pruritus (搜索) associated with allergic dermatitis (搜索) in dogs six months of age and older, NUMELVI (搜索) establishes a unique position in the veterinary therapeutics market. The approval represents more than 70 years of innovation and commitment to animal health from Merck Animal Health (搜索).
McKinney noted that NUMELVI (搜索) provides veterinary professionals with "a groundbreaking, first-of-its-kind solution aimed at improving the health and well-being of dogs as young as six months of age to mature dogs – and ultimately providing peace of mind for the people who care for them."
The product will be available through veterinary clinics and hospitals nationwide beginning in spring 2026, offering a new therapeutic option for managing a condition that significantly affects both canine patients and the human-animal bond.